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Introduction:Most adjuvant lung cancer trials only report first sites
of failure. The relative timing of local (i.e., local/regional) versus
distant recurrence after surgery could potentially affect reported
rates of local failure. We assessed this phenomenon in a large group
of patients undergoing surgery for early-stage lung cancer.
Methods: This institutional review board-approved retrospective
study identified all patients who underwent surgery at Duke Uni-
versity Medical Center for pathologic stages I to II non-small cell
lung cancer between 1995 and 2005. Medical records and pertinent
radiographs were reviewed to assess for local and distant sites of
recurrence. Both first and subsequent failures were examined. The
time interval between surgery and date of local and/or distant failure
was compared using the Mann-Whitney U test.
Results: Of 975 patients undergoing surgery, 250 patients devel-
oped recurrent disease (43 local only, 110 distant only, and 97 both).
The median time from surgery to local failure was 13.9 months
(range, 1–79). The median time to distant failure was 12.5 months
(range, 1–79 months). These were not significantly different (p 
0.34). Among 97 patients who experienced both local and distant
failure, 72 (74%) failed at both sites simultaneously, 19 (20%) failed
at local sites first, and 6 (6%) failed at distant sites first.
Conclusions: The time interval from surgery to either local or
distant failure is not significantly different. Patterns of failure anal-
yses in which only first sites of failure are scored will underestimate
the frequency of local recurrence. Nevertheless, the magnitude of
this error is expected to be small.
Key Words: Non-small cell lung cancer, Local recurrence, Distant
recurrence, Patterns of failure.
(J Thorac Oncol. 2010;5: 211–214)
Surgery is the preferred initial treatment for early-stagenon-small cell lung cancer (NSCLC). Adjuvant chemo-
therapy is often recommended, depending on disease stage,
size of the primary tumor, and other pathologic characteris-
tics. Postoperative radiation therapy is generally not recom-
mended in the absence of positive surgical margins or other
adverse features.
The risk of local (i.e., local/regional) recurrence after
surgery for early-stage NSCLC is generally considered to be
small in comparison with the risk of distant recurrence.
Nevertheless, reported rates of local failure after surgery for
stage I NSCLC vary from as low as 6 to 8%1–3 to as high as
20 to 28%.4–6 Reported rates for stage II disease range from
20 to 40%.7–9
An accurate understanding of patterns of failure after
surgery is essential to guide appropriate adjuvant therapy. In
prospective studies, for ease of reporting, typically, only first
sites of failure are recorded. Patterns of failure are most
commonly reported as: local only, distant only, or local plus
distant. Awareness of the relative timing of local and distant
failure is necessary if only first sites of failure are scored. For
example, the rate of local failure may be underreported if
distant failures become clinically evident earlier in the natural
history of the disease.
We have previously assessed the rate of local failure
after surgery for early-stage NSCLC at Duke.10 In this report,
we analyze the relative timing of local versus distant failure,
to assess whether this issue may affect rates of local failure
reported in prospective studies.
PATIENTS AND METHODS
This institutional review board-approved retrospective
study was performed by searching the Duke Comprehensive
Cancer Center database for patients who underwent surgery
for T1–2 N0–1 NSCLC at Duke University between 1995
and 2005. Patients who received neoadjuvant therapy (che-
motherapy and/or radiation therapy), presented with synchro-
nous primary lung tumors, or had a prior history of lung
cancer were excluded. The patient’s medical records and
pertinent radiologic imaging were reviewed to characterize
each patient’s demographic information, obtain surgical and
pathologic details, and score patterns of failure after surgery.
Departments of *Radiation Oncology, and †Cancer Center Biostatistics,
Duke University Medical Center, Durham; and ‡Department of Radia-
tion Oncology, University of North Carolina, Chapel Hill, North Caro-
lina.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Chris R. Kelsey, MD, Department of Radiation
Oncology, Duke University Medical Center Box 3085, Durham, NC
27710. E-mail: kelse003@mc.duke.edu
Presented at the 49th Meeting of the American Society for Therapeutic
Radiology and Oncology (ASTRO), October 28 – November 1, 2007 in
Los Angeles, CA.
Copyright © 2010 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0502-0211
Journal of Thoracic Oncology • Volume 5, Number 2, February 2010 211
Although follow-up was not standardized, patients
were generally seen every 3 to 6 months after surgery for the
first 5 years and annually thereafter. Follow-up imaging
typically consisted of a chest x-ray. Further imaging, includ-
ing computed tomography (CT), magnetic resonance imag-
ing, bone scan, and positron emission tomography (PET),
was obtained at the discretion of the treating physician and
was generally obtained when patients presented with con-
cerning symptoms or the chest x-ray was abnormal. Simi-
larly, at the time of recurrence, radiographic studies were
performed at the discretion of the treating physicians.
Disease recurrence at the surgical resection margin,
ipsilateral hilum, and/or mediastinum was considered a local
failure. All other sites of failure, including the supraclavicular
fossa and contralateral hilum, were considered distant fail-
ures. Nodal failures were defined as a new or enlarging lymph
node 1 cm on short axis on CT or hypermetabolic on PET,
which in the patient’s subsequent clinical follow-up was
consistent with a true local failure. Local and distant failures
were scored independently. All failures were reviewed by
two authors (J.B. and C.K.) and often required clinical judg-
ment, in as much as pathologic documentation was not
always performed.
When local and distant failures were detected in the
same patient within 30 days of one another, this was defined
as a “simultaneous failure.” When local and distant failures
occurred more than 30 days apart, this was defined as a
“sequential failure.” The time interval between surgery and
date of failure for local and distant recurrence was compared
using the Mann-Whitney U test.
RESULTS
We identified 975 patients who underwent surgery for
T1–2 N0–1 NSCLC in the defined interval. Median fol-
low-up was 33 months (range, 1–149). Patient characteristics
and surgical/pathologic details are found in Table 1. Most
patients had stage I disease (45% IA and 40% IB). Hilar
lymph nodes (N1, levels 10–14) were sampled in 81% of
patients. The median number of N1 lymph nodes sampled
was 4 (range, 1–31). Mediastinal lymph nodes (N2, levels
1–9) were sampled or dissected in 85% of patients. The
median number of mediastinal lymph node stations exam-
ined was 4 (range, 1–9). Surgical margins were positive in
4% of patients.
Adjuvant chemotherapy was administered to 7% of
patients, most frequently carboplatin and paclitaxel, although
a number of regimens were used. Adjuvant radiation therapy
was given to 3%, primarily for positive surgical margins.
Disease recurrence developed in 250 patients. Local
recurrence was identified in 140 patients, and distant failure
was identified in 207 patients. Local recurrences were con-
firmed by means of biopsy in 47%, PET in 33%, and CT in
20%. Distant recurrences were confirmed by biopsy in 50%,
PET in 25%, and other imaging (CT, magnetic resonance
imaging, or bone scan) in 25%. The 5-year actuarial rate of
local and distant recurrence was 23% (95% confidence inter-
val, 19–26%) and 34% (95% confidence interval, 30–39%),
respectively.10
TABLE 1. Patient Characteristics
Characteristic N (%)
Age, yr
Median (range) 67 (20–93)
Gender
Male 533 (55)
Female 442 (45)
Race
White 824 (85)
Black 124 (13)
Other 23 (2)
Surgical procedure
Wedge 161 (17)
Segmentectomy 41 (4)
Lobectomy 668 (68)
Sleeve resection 36 (4)
Pneumonectomy 69 (7)
Surgical approach
Open 600 (62)
VATS 375 (38)
Hilar lymph node sampling
Yes 790 (81)
No 185 (19)
Mediastinal lymph node sampling
Yes 824 (85)
No 151 (15)
Size, cm
Median, range 2.6 (0.3–13)
Histology
Adenocarcinoma 441 (45)
Squamous cell 358 (37)
Large cell 48 (5)
Bronchioloalveolar 28 (3)
Adenosquamous 6 (1)
NSCLC NOS 94 (10)
Histologic differentiation
Well 77 (8)
Moderate 424 (43)
Poor 298 (31)
NS 176 (18)
Lymphovascular space invasion
Yes 210 (22)
No/NS 765 (78)
Visceral pleural invasion
Yes 201 (21)
No/NS 774 (79)
Pathologic stage
IA 435 (45)
IB 385 (39)
IIA 43 (4)
IIB 112 (11)
Surgical margins
Negative 939 (96)
Positive 36 (4)
Adjuvant chemotherapy
Yes 65 (7)
No 910 (93)
Adjuvant radiation therapy
Yes 33 (3)
No 941 (97)
VATS, video-assisted thoracoscopic surgery; NSCLC, non-small cell lung cancer;
NOS, not otherwise stated; NS, not significant.
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Of the 250 failures, 43 (17%) were confined to local
sites, 110 (44%) were confined to distant sites, and 97 (39%)
included both local and distant sites (Figure 1). Of the 97
patients who failed at both local and distant sites, most (74%)
did so simultaneously. Only six patients developed a sequen-
tial local recurrence, documented more than 30 days after a
distant recurrence was identified (Figure 2). Thus, the crude
rate of local failure would be underestimated by 0.6% (6 of
975) if only first sites of failure are reported.
Patients who developed recurrent disease confined to
local sites (n  43) underwent comprehensive restaging
examinations to evaluate for distant metastases before initi-
ation of salvage local therapy (surgery and/or radiation ther-
apy). For those patients who developed a recurrence appar-
ently confined to distant sites (n  110), most underwent
either CT (44%) or PET (33%) imaging to evaluate for a
concurrent local recurrence. The remainder either had a
chest x-ray performed (17%) or underwent no imaging of
the chest (6%).
There was no difference in the time interval between
surgery and the development of a local failure and the time
interval between surgery and the development of a distant
failure (p  0.34) (Figure 3). The median time from
surgery to local failure was 13.9 months (range, 1–79). The
median time from surgery to distant failure was 12.5
months (range, 1–79).
DISCUSSION
Lung cancer is the leading cause of cancer mortality in
the United States.11 Notwithstanding optimal surgery, the risk
of recurrence is high, even with early-stage disease. Lung
cancer can recur at sites proximal to the original tumor (i.e.,
local/regional failure) or at distant sites. The risk of local
recurrence after surgery for early-stage NSCLC has not been
well defined but is generally felt to be low and overshadowed
by the risk of distant recurrence. Nevertheless, few prospec-
tive studies report patterns of failure. Furthermore, the opti-
mal method of reporting patterns of failure is not clear. Most
prospective studies only report first sites of failure, as op-
posed to cumulatively assessing and recording sites of recur-
rence. Recording only the first site(s) of failure has obvious
practical advantages. In addition, it could be argued that the
importance of a local recurrence that is detected after distant
metastases have developed is of little clinical consequence.
Nevertheless, as systemic therapy improves,12,13 achieving
local control will likely assume greater importance.
To better study this issue, we assessed the risk of local
and distant recurrence in a cumulative fashion in patients who
underwent surgery for early-stage NSCLC at Duke Univer-
FIGURE 1. Distribution of failures among 250 patients
with stages I to II non-small cell lung cancer who recurred
after surgery. Local (i.e., local/regional) and distant failures
developing within 30 days of each other were considered
“simultaneous.”
FIGURE 2. Time to local and distant failure is displayed for
97 patients with stages I to II non-small cell lung cancer who
developed both a local and distant recurrence. A line of
unity is shown.
FIGURE 3. The cumulative incidence of local and distant
failure for 250 patients with stage I to II non-small cell lung
cancer who recurred after surgery. There was no difference
in the time interval between local and distant failures (me-
dian 13.9 versus 12.5 months, respectively).
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sity. The 5-year actuarial risk of local and distant recurrence
was 23% and 34%, respectively, and has been previously
reported.10 In this analysis, we analyzed the timing of local
and distant failures after surgery of early-stage NSCLC. We
further estimated how much the risk of local recurrence
would be underestimated if only first failures are scored.
We found that distant recurrences occur, on average,
12.5 months after surgery compared with 13.9 months for
local recurrences, a difference which is not statistically sig-
nificant. Furthermore, we found that most patients who re-
curred at local sites did so without evidence of distant disease
or with synchronous distant metastases. Only 4.2% of local
recurrences occurred more than 30 days after a distant failure.
Put another way, when considering all recurrences, the crude
local failure rate would be underestimated by less than 1% if
only first sites of failure are scored. This would suggest that
early-stage lung cancers, which are destined to recur at
local/regional sites, likely disseminate early in the course of
the disease. This may explain, in part, why randomized trials
of postoperative radiation therapy (without chemotherapy)
consistently improved local control but did not improve
overall survival.6,7,14 Unless distant disease is better con-
trolled with chemotherapy, further local therapy will be of
little consequence.
We acknowledge that there are limitations to our study.
First, a systematic method of follow-up, including imaging,
would be optimal to evaluate patterns of failure after surgery.
Unfortunately, given the retrospective nature of this analysis
and the 11-year time period which it covers, this was not the
case. Second, a significant number of patients with “distant
only” recurrences did not undergo optimal imaging of the
chest at the time of recurrence. Thus, some local failures
might not have been detected. Third, only approximately 50%
of recurrences were pathologically confirmed. This is typical
because many patients present shortly after initial treatment
with clear progression and a biopsy is not always deemed
necessary. It is important to note that the percentage of
recurrences documented with biopsy and PET was similar
between patients who developed a local versus distant recur-
rences. The primary strength of this study is the large number
of patients who were carefully analyzed for patterns of failure
after surgery for early-stage NSCLC.
In summary, we found that most local failures occur
alone or synchronously with distant metastases. Reporting
only first sites of failures does not seem to appreciably
diminish the true rate of local recurrence in patients with
early-stage NSCLC.
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